IMA401 TCER® in Recurrent and/or Refractory Solid Tumors, Alone or in Combination With a Checkpoint Inhibitor

Inclusion Criteria: * Patients must have voluntarily signed a written ICF, be able to understand and comply with clinical trial procedures * Patients ≥ 18 years old * Patients must have pathologically confirmed and documented advanced and/or metastatic NSCLC or HNSCC, other solid tumor may be considered * Confirmed HLA status and IMA401 tumor target MAGE-A4 and/or MAGE-A8 expression * Life expectancy \> 2 months * ECOG Performance Status of 0 to 1 * Measurable disease according to RECIST 1.1 * Adequate baseline hematologic, renal and hepatic function; acceptable coagulation status * Patients must have recurrent and/or refractory solid tumors and must have received or not be eligible for all available indicated standard of care treatments * The patient must have recovered from any side effects of prior therapy to Grade 1 or lower (except for non-clinically significant toxicities; e.g., alopecia, vitiligo) prior to treatment start. As determined by the investigator, the patient may still be eligible if the patient has not fully recovered from Grade ≥ 2 toxicities, in case if these toxicities are not anticipated to further improve (e.g., chronic peripheral neuropathy) and such toxicities are not anticipated to worsen with the IMA401 therapy Exclusion Criteria: * Other active malignancies that require treatment or that might interfere with the trial endpoints (ongoing adjuvant anti-hormonal treatment is allowed) * History of hypersensitivity to components of IMA401, CPI treatm…